https://orcid.org/0000-0002-6198-239X
References
- Knutson SK , KawanoS , MinoshimaYet al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther.13(4), 842–854 (2014).
- Zhang J , ZhengYG. SAM/SAH analogs as versatile tools for SAM-dependent methyltransferases. ACS Chem. Biol.11(3), 583–597 (2016).
- Campagna-Slater V , MokMW , NguyenKT , FeherM , NajmanovichR , SchapiraM. Structural chemistry of the histone methyltransferases cofactor binding site. J. Chem. Inf. Model.51(3), 612–623 (2011).
- Qian C , ZhouM-M. SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cell. Mol. Life Sci.63(23), 2755–2763 (2006).
- Wu H et al. Structural biology of human H3K9 methyltransferases. PLoS ONE5(1), e8570 (2010).
- Erdmann A , HalbyL , FahyJ , ArimondoPB. Targeting DNA methylation with small molecules: what’s next?J. Med. Chem.58(6), 2569–2583 (2015).
- Handa V , JeltschA. Profound flanking sequence preference of Dnmt3a and Dnmt3b mammalian DNA methyltransferases shape the human epigenome. J. Mol. Biol.348(5), 1103–1112 (2005).
- Emperle M et al. The DNMT3A R882H mutant displays altered flanking sequence preferences. Nucleic Acids Res.46(6), 3130–3139 (2018).
- Lavogina D , EnkvistE , UriA. Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem5(1), 23–34 (2010).
- Miletić V , OdorčićI , NikolićP , SvedružićŽM. In silico design of the first DNA-independent mechanism-based inhibitor of mammalian DNA methyltransferase Dnmt1. PloS ONE12(4), e0174410 (2017).
- Halby L , MenonY , RilovaEet al. Rational design of bisubstrate-type analogues as inhibitors of dna methyltransferases in cancer cells. J. Med. Chem.60(11), 4665–4679 (2017).
- Halby L et al. Hijacking DNA methyltransferase transition state analogues to produce chemical scaffolds for PRMT inhibitors. Philos. Trans. R. Soc. Lond. B. Biol. Sci.373(1748), (2018).
- Basavapathruni A , JinL , DaigleSRet al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem. Biol. Drug Des.80(6), 971–980 (2012).
- Chen C et al. Discovery of novel Dot1L Inhibitors through a structure-based fragmentation approach. ACS Med. Chem. Lett.7(8), 735–740 (2016).
- Gerhart SV et al. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci. Rep.8(1), 9711–9726 (2018).
- Brehmer D et al. Abstract DDT02-04: a novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models. Cancer Res.77(Suppl. 13), DDT02-04–DDT02-04 (2017).
- Tao H , YanX , ZhuK , ZhangH. Discovery of novel PRMT5 inhibitors by virtual screening and biological evaluations. Chem. Pharm. Bull. (Tokyo)67(4), 382–388 (2019).
- Ngo L , BrownT , ZhengYG. Bisubstrate inhibitors to target histone acetyltransferase 1. Chem. Biol. Drug Des.93(5), 865–873 (2019).
- Osborne T , RoskaRLW , RajskiSR , ThompsonPR. In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J. Am. Chem. Soc.130(14), 4574–4575 (2008).